Clinical trialPhase 1Active not recruiting
Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI
SPECT/CT Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI ([99mTc]Tc- HYNIC-FAPI) in Metastatic Cancer Patients
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 26 February 2026
- Expected end
- 31 May 2027
- Enrollment
- 15 participants
- Sites
- 1
- Primary outcomes
- Gamma camera-based whole-body [99mTc]Tc-HYNIC-FAPI uptake value (%).; SPECT/CT-based [99mTc]Tc-HYNIC-FAPI value in tumor lesions (counts and SUV); SPECT/CT -based [99mTc]Tc-HYNIC-FAPI background uptake value (counts and SUV).; Tumor-to-background ratio (SPECT/CT).
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 25 June 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The study should evaluate the biological distribution of 99mTc-HYNIC-FAPI in metastatic cancer patients.
Detailed description public domain (ClinicalTrials.gov)
The primary objective are: 1. To assess the distribution of \[99mTc\]Tc- HYNIC-FAPI in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of \[99mTc\]Tc- HYNIC-FAPI. 3. To study the safety and tolerability of the drug \[99mTc\]Tc- HYNIC-FAPI after a single injection in a diagnostic dosage. The secondary objective are: 1\. To compare the obtained \[99mTc\]Tc- HYNIC-FAPI SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in metastatic cancer patients.